Disclosures for "Phase Ⅱ Clinical Trial of NKT Cell-targeting Glycolipid OCH-NCNP1 for Patients with Relapsing Multiple Sclerosis"
-
Tomoko Okamoto has nothing to disclose.
-
Wakiro Sato has nothing to disclose.
-
Youwei Lin has nothing to disclose.
-
Yukio Kimura has nothing to disclose.
-
Noriko Sato has nothing to disclose.
-
Dr. Shimizu has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen Japan.. Dr. Shimizu has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis Pharma.
-
Yoichiro Nishida has nothing to disclose.
-
Dr. Yokota has nothing to disclose.
-
Mr. Taketsuna has nothing to disclose.
-
Mr. Okada has nothing to disclose.
-
The institution of Dr. Ishizuka has received research support from Japan Agency for Medical Research and Development.
-
Dr. Nakamura has nothing to disclose.
-
Prof. Miyajke has received research support from Japan.
-
The institution of Dr. Takahashi has received research support from Nihon Medi-Physics Co. Limit.. The institution of Dr. Takahashi has received research support from Takeda Pharmaceutical Company Limited.
-
Dr. Yamamura has nothing to disclose.